Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy

Journal of Thoracic Oncology

Volumn 5, Issue 9, 2010, Pages 1397-1403

  Brunetto, Andre T ^a   Carden, Craig P ^a   Myerson, James ^a   Faria, Ana Luisa ^a   Ashley, Sue ^a   Popat, Sanjay ^a   O'Brien, Mary E R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Dose intensity; Dose reduction; Neutropenia; NSCLC; Overall survival; Progression free survival

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FEVER; HEARING LOSS; HUMAN; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; TINNITUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77956265855     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181eba7f9     Document Type: Article

References (27)

1. Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol 2005;23:3175-3185.
2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311: 1904-1911.
3. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for non-small cell lung cancer be platinum based? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335-345.
4. Effects of vinorelbine on quality of life and survival of elderly patients with non-small cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group (ELVIS). J Natl Canc Inst 1999;91:66-72.
5. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
6. Group FAS. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602-611.
7. Lorigan P, Woll P, O'Brien ME, et al. Randomized phase III trial of dose dense chemotherapy supported by whole blood progenitors in better prognosis small cell lung cancer. J Natl Canc Inst 2005;97:666-674.
8. Tibaldi C, Ricci S, Russo F, et al. Increased dose intensity of gemcit-abine in advanced non-small cell lung cancer (NSCLC): a multi-center phase II study in elderly patients from the "polmone toscano group" (POLTO). Lung Cancer 2005;48:121-127.
9. Font A, Moyano A, Puerto J, et al. Increasing dose-intensity of cisplatin-etoposide in advanced non-small cell lung cancer. A phase III randomized trial of Spanish Lung Cancer Group. Cancer 1999; 85:855-863.
10. Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763-1766.
11. Mayers C, Panzarella T, Tannock IF. An analysis of the prognostic effects of inclusion criteria in clinical trials and of myelo-suppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246-2257.
12. Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837-1842.
13. Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteo-sarcoma. N Eng J Med 1974;291:998-1000.
14. Rocconi RP, Matthews KS, Barnes MV, et al. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients. Gynecol Oncol 2008;108:336-341.
15. Banerji U, Ashley S, Coward J, et al. The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer. Lung Cancer 2006;54:371-377.
16. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutro-penia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomized trials. Lancet Oncol 2005;6:669-677.
17. Kishida Y, Kawahara M, Teramukai S, et al. Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03. Br J Cancer 2009;101:1537-1542.
18. Lara PN, Lau DH, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol 2002;3:53-58.
19. Gralla LJ, Thatcher N. Quality-of-life assessment in advanced lung cancer: considerations for evaluation in patients receiving chemotherapy. Lung Cancer 2004;46:S41-S47.
20. Longo DL, Duffey PL, DeVita VT Jr, et al. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991;9:2042-2051.
21. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991.
22. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
23. d'Amato TA, Pettiford BL, Schuchert MJ, et al. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy. Ann Surg Oncol 2009;16: 2848-5285.
24. Kang CH, Jang BG, Kim DW, et al. Differences in the expression profiles of excision repair crosscomplementation group 1, X-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol 2009;4:1307-1312.
25. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007;25:2741-2746.
26. Gridelli C Cigolari S, Gallo C, et al. Activity and toxicity of gemcitabine and gemcitabine +vinorelbine in advanced non-small cell lung cancer elderly patients. Phase data from the Multicenter Italian Cancer in the Elderly (MILES) randomized trial. Lung Cancer 2001;31:277-284.
27. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial for the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3025-3034.